From the Audition in the Press to TV, Web, and Print Advertising. Pfizer and Amgen demonstrate how to launch a branded spokesperson campaign starting from a bit of over-the-top unregulated press relations to fully regulated TV, print, and Web advertising. It must be costing a mint!
Let's look 'under the hoods' of two pharma-sponsored mobile apps and compare disclaimers. We'll compare Janssen's PASI calculator, which has an update disclaimer, with the new AFib Educator 2.0 app developed by Sanofi-Aventis.
This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
Looming Challenges Cloud Implementation. This article reviews the strategic implications of the Sunshine Act and also presents highlights of the draft regulations rule released by the Centers for Medicare and Medicaid Services on December 15, 2011.
Rules for Third-Party Engagement in Patient/Physician Social Networks. A Social Media Policy is not just an agreement that users must abide by. More importantly, it is a PROMISE to users from site owners/sponsors concerning how they will protect or attempt to protect user-generated content, personal conversations, interactions, and engagements with third-parties on the site. These policies should comply with as-yet-to-be-determined, universally accepted 'fair social media practice principles.'
Talk about having your cake and eating it too! Commercial funding of continuing medical education (CME) and the potential for bias appear to concern many physicians, yet only a TINY MINORITY (7%) are willing to pay registration fees to eliminate or offset commercial funding sources, according to a report in the May 9, 2011, issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
David Epstein, head of Novartis Pharmaceuticals, said eighty percent of his company's sales reps will give up their PCs for iPads in 2012. Will they do it?
Has It Been Found? What Does It Reveal About Pfizer's Social Media Implementation Plan?. Ray Kerins (@raykerins), Vice President of Worldwide Communications at Pfizer, talks about Pfizer's 'groundbreaking internal Social Media Playbook' but won't show it to us. What can be in the playbook? How many people does Pfizer dedicate to social media? This article discusses those questions and offers a peek into a playbook contender.
The Death of the Traditional Pharma Salesman and the Birth of the 'Sales Cyborg.' eDetailing in one form or another seems to be making a comeback since the recession hit the drug industry in 2007 and 2008. Which is the 'chicken' and which is the 'egg'? Did the uptick in adoption of eDetailing technology lead to the recent layoff of pharma reps or were reps laid off because of the economy and subsequently replaced by machines?